Overview

Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of a New Ultra Low Molecular Weight Heparin (RO-14) Administered Subcutaneously Increasing Single-doses to Healthy Male Volunteers

Status:
Completed

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

Clinical trial to evaluate the tolerability and pharmacokinetics of a new ultra low molecular weight heparin (RO-14) administered subcutaneously increasing single-doses to healthy male volunteers

Phase:

Phase 1

Details

Lead Sponsor:

Rovi Pharmaceuticals Laboratories

Treatments:

Dalteparin
Heparin
Heparin, Low-Molecular-Weight